Back to resultsBioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
Primary Purpose
Herpes Zoster, Shingles, Genital Herpes
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Valacyclovir Hydrochloride
Sponsored by
About this trial
This is an interventional treatment trial for Herpes Zoster
Eligibility Criteria
Inclusion Criteria:
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
Exclusion Criteria:
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to valacyclovir hydrochloride or any comparable or similar product.
Sites / Locations
- PRACs Institute, Ltd.
Outcomes
Primary Outcome Measures
bioequivalence determined by statistical comparison Cmax
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01132729
Brief Title
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
Official Title
A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Valacyclovir Caplets Under Fasting Conditions
Study Type
Interventional
2. Study Status
Record Verification Date
January 2018
Overall Recruitment Status
Completed
Study Start Date
September 2006 (undefined)
Primary Completion Date
September 2006 (Actual)
Study Completion Date
September 2006 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Roxane Laboratories
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of this study was to prove the bioequivalence of Valacyclovir Hydrochlorothiazide Caplet under fasting conditions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Herpes Zoster, Shingles, Genital Herpes
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
48 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Valacyclovir Hydrochloride
Other Intervention Name(s)
Valtrex
Intervention Description
1000 mg caplet
Primary Outcome Measure Information:
Title
bioequivalence determined by statistical comparison Cmax
Time Frame
8 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
Exclusion Criteria:
Positive test for HIV, Hepatitis B, or Hepatitis C.
Treatment with known enzyme altering drugs.
History of allergic or adverse response to valacyclovir hydrochloride or any comparable or similar product.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alan Copa, PharmD
Organizational Affiliation
PRACs Institute, Ltd.
Official's Role
Principal Investigator
Facility Information:
Facility Name
PRACs Institute, Ltd.
City
Fargo
State/Province
North Dakota
ZIP/Postal Code
58104
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
We'll reach out to this number within 24 hrs